97 related articles for article (PubMed ID: 22054387)
1. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel.
Ito M; Saito K; Yasuda Y; Sukegawa G; Kubo Y; Numao N; Kitsukawa S; Urakami S; Yuasa T; Yamamoto S; Yonese J; Fukui I
Urology; 2011 Nov; 78(5):1131-5. PubMed ID: 22054387
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
Beer TM; Lalani AS; Lee S; Mori M; Eilers KM; Curd JG; Henner WD; Ryan CW; Venner P; Ruether JD; Chi KN;
Cancer; 2008 Jun; 112(11):2377-83. PubMed ID: 18428198
[TBL] [Abstract][Full Text] [Related]
3. Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.
Pond GR; Armstrong AJ; Wood BA; Leopold L; Galsky MD; Sonpavde G
BJU Int; 2012 Dec; 110(11 Pt B):E461-8. PubMed ID: 22520631
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
Buonerba C; Federico P; D'Aniello C; Rescigno P; Cavaliere C; Puglia L; Ferro M; Altieri V; Perdonà S; De Placido S; Di Lorenzo G
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer.
Takaha N; Okihara K; Kamoi K; Hongo F; Iwata T; Yano K; Ueda T; Takeuchi I; Yamada T; Kawauchi A; Miki T
Urol Int; 2011; 87(3):263-9. PubMed ID: 21876321
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.
Noguchi M; Moriya F; Suekane S; Matsuoka K; Arai G; Matsueda S; Sasada T; Yamada A; Itoh K
Prostate; 2012 Jun; 72(8):834-45. PubMed ID: 21932426
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.
Italiano A; Ortholan C; Oudard S; Pouessel D; Gravis G; Beuzeboc P; Bompas E; Fléchon A; Joly F; Ferrero JM; Fizazi K
Eur Urol; 2009 Jun; 55(6):1368-75. PubMed ID: 18706755
[TBL] [Abstract][Full Text] [Related]
9. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
[TBL] [Abstract][Full Text] [Related]
10. Re: Ito et al. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel (Urology 2011;78:1131-1135).
Kathpalia R; Mandal S; Sankhwar S
Urology; 2012 Jun; 79(6):1414; author reply 1414-5. PubMed ID: 22656421
[No Abstract] [Full Text] [Related]
11. Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel.
Strijbos MH; Gratama JW; Schmitz PI; Rao C; Onstenk W; Doyle GV; Miller MC; de Wit R; Terstappen LW; Sleijfer S
Eur J Cancer; 2010 Jul; 46(11):2027-35. PubMed ID: 20399640
[TBL] [Abstract][Full Text] [Related]
12. Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy.
Helley D; Banu E; Bouziane A; Banu A; Scotte F; Fischer AM; Oudard S
Eur Urol; 2009 Sep; 56(3):479-84. PubMed ID: 18585841
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
Kibel AS; Rosenbaum E; Kattan MW; Picus J; Dreicer R; Klein EA; Chatta GS; Nelson JB; DiPaola RS; Roth BJ; Cookson MS; Wilding G; Jarrard DF; Beer TM; Ryan CW; Petrylak DP; Benson MC; Partin AW; Garrett-Mayer E; Eisenberger MA
J Urol; 2007 May; 177(5):1777-81. PubMed ID: 17437819
[TBL] [Abstract][Full Text] [Related]
14. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Linton A; Pond G; Clarke S; Vardy J; Galsky M; Sonpavde G
Clin Genitourin Cancer; 2013 Dec; 11(4):423-30. PubMed ID: 23816526
[TBL] [Abstract][Full Text] [Related]
15. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
16. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
Oudard S; Banu E; Medioni J; Scotte F; Banu A; Levy E; Wasserman J; Kacso G; Andrieu JM
BJU Int; 2009 Jun; 103(12):1641-6. PubMed ID: 19210673
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
[TBL] [Abstract][Full Text] [Related]
18. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
Scher HI; Jia X; Chi K; de Wit R; Berry WR; Albers P; Henick B; Waterhouse D; Ruether DJ; Rosen PJ; Meluch AA; Nordquist LT; Venner PM; Heidenreich A; Chu L; Heller G
J Clin Oncol; 2011 Jun; 29(16):2191-8. PubMed ID: 21483004
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.
Di Lorenzo G; Buonerba C; Faiella A; Rescigno P; Rizzo M; Autorino R; Perdonà S; Riccardi N; Scagliorini S; Scognamiglio F; Masala D; Ferro M; Palmieri G; Aieta M; Marinelli A; Altieri V; De Placido S; Cartenì G
BJU Int; 2011 Jan; 107(2):234-9. PubMed ID: 20590545
[TBL] [Abstract][Full Text] [Related]
20. Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors.
Caffo O; Pappagallo G; Brugnara S; Caldara A; di Pasquale MC; Ferro A; Frisinghelli M; Murgia V; Russo LM; Soini B; Valduga F; Veccia A; Galligioni E
Urology; 2012 Mar; 79(3):644-9. PubMed ID: 22386418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
